{"id":1019992,"date":"2026-11-11T10:42:44","date_gmt":"2026-11-11T15:42:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/"},"modified":"2026-11-11T10:42:44","modified_gmt":"2026-11-11T15:42:44","slug":"ultragenyx-to-participate-at-investor-conferences-in-london","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/","title":{"rendered":"Ultragenyx to Participate at Investor Conferences in London"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NOVATO, Calif., Nov.  11, 2026  (GLOBE NEWSWIRE) &#8212; Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in upcoming investor conferences.<\/p>\n<p>\n        <strong>UBS Global Biopharma Conference 2026 <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Monday, November 16, 2026, Emil Kakkis, M.D., Ph.D., President and Chief Executive Officer, Eric Crombez, M.D., Chief Medical Officer, and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1&#215;1 meetings.\n<\/li>\n<\/ul>\n<p>\n        <strong>2026 Jefferies Global Healthcare Conference <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Tuesday, November 17, 2026, Emil Kakkis, Eric Crombez, and Howard Horn will participate in a fireside chat and host 1&#215;1 meetings.\n<\/li>\n<\/ul>\n<p>The live and archived webcast of the fireside chat will be accessible from the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HZ0VJ_aqHOXqXLWRibMS8_t5zDTHIeQytCW1RstOQIHftWxoeAlxgKYnSPmcdrPpwHeIj5v0arPyQnBnlroZ0q9CXyaUryoauoJjH8gXkhkFUNOVBs2ZX5PgvZpAMb3MWFiRy0IiDNc4ZseoVm2Ilultazw8xkpm9HyDEjUf3LQ=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.ultragenyx.com\/events-presentations<\/a>.<\/p>\n<p>\n        <strong>About Ultragenyx<\/strong>\n      <\/p>\n<p>Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.<\/p>\n<p>For more information on Ultragenyx, please visit the company&#8217;s website at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N78Bchp-xSbKCFo3Q6nGe5VMh2HTkvmTiiZGdeoQPtVkm-h2Zq_IHJGtwjG-O0V-0AlYaSTnneEDRoRepw2wQ90OR6Pc_N1T5MA9BjM3MwM=\" rel=\"nofollow\" target=\"_blank\">www.ultragenyx.com<\/a>.<\/p>\n<p>Contacts \u2013 Ultragenyx<br \/>Investors<br \/>Joshua Higa<br \/>ir@ultragenyx.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDY1NyM3OTU3NzU0IzIwMDkyOTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDA0MzRlODktNDgzYi00YjY4LTlhYmYtMjA5ZThiYWZhNzBiLTEwMjA4NjQtMjAyNi0xMS0xMS1lbg==\/tiny\/Ultragenyx-Pharmaceutical-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) &#8212; Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in upcoming investor conferences. UBS Global Biopharma Conference 2026 Monday, November 16, 2026, Emil Kakkis, M.D., Ph.D., President and Chief Executive Officer, Eric Crombez, M.D., Chief Medical Officer, and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1&#215;1 meetings. 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 2026, Emil Kakkis, Eric Crombez, and Howard Horn will participate in a fireside chat and host 1&#215;1 meetings. The live and archived webcast of the fireside chat will be accessible from the company\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ultragenyx to Participate at Investor Conferences in London&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1019992","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ultragenyx to Participate at Investor Conferences in London - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ultragenyx to Participate at Investor Conferences in London - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) &#8212; Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in upcoming investor conferences. UBS Global Biopharma Conference 2026 Monday, November 16, 2026, Emil Kakkis, M.D., Ph.D., President and Chief Executive Officer, Eric Crombez, M.D., Chief Medical Officer, and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1&#215;1 meetings. 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 2026, Emil Kakkis, Eric Crombez, and Howard Horn will participate in a fireside chat and host 1&#215;1 meetings. The live and archived webcast of the fireside chat will be accessible from the company\u2019s &hellip; Continue reading &quot;Ultragenyx to Participate at Investor Conferences in London&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-11T15:42:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDY1NyM3OTU3NzU0IzIwMDkyOTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ultragenyx to Participate at Investor Conferences in London\",\"datePublished\":\"2026-11-11T15:42:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/\"},\"wordCount\":214,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDY1NyM3OTU3NzU0IzIwMDkyOTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/\",\"name\":\"Ultragenyx to Participate at Investor Conferences in London - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDY1NyM3OTU3NzU0IzIwMDkyOTE=\",\"datePublished\":\"2026-11-11T15:42:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDY1NyM3OTU3NzU0IzIwMDkyOTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDY1NyM3OTU3NzU0IzIwMDkyOTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-london\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ultragenyx to Participate at Investor Conferences in London\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ultragenyx to Participate at Investor Conferences in London - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/","og_locale":"en_US","og_type":"article","og_title":"Ultragenyx to Participate at Investor Conferences in London - Market Newsdesk","og_description":"NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) &#8212; Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in upcoming investor conferences. UBS Global Biopharma Conference 2026 Monday, November 16, 2026, Emil Kakkis, M.D., Ph.D., President and Chief Executive Officer, Eric Crombez, M.D., Chief Medical Officer, and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1&#215;1 meetings. 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 2026, Emil Kakkis, Eric Crombez, and Howard Horn will participate in a fireside chat and host 1&#215;1 meetings. The live and archived webcast of the fireside chat will be accessible from the company\u2019s &hellip; Continue reading \"Ultragenyx to Participate at Investor Conferences in London\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-11T15:42:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDY1NyM3OTU3NzU0IzIwMDkyOTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ultragenyx to Participate at Investor Conferences in London","datePublished":"2026-11-11T15:42:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/"},"wordCount":214,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDY1NyM3OTU3NzU0IzIwMDkyOTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/","name":"Ultragenyx to Participate at Investor Conferences in London - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDY1NyM3OTU3NzU0IzIwMDkyOTE=","datePublished":"2026-11-11T15:42:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDY1NyM3OTU3NzU0IzIwMDkyOTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDY1NyM3OTU3NzU0IzIwMDkyOTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-london\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ultragenyx to Participate at Investor Conferences in London"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1019992"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019992\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1019992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1019992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1019992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}